[PHP339] Sofosbuvir: The Failure of Pricing Policies In The European Union

[PHP339] Sofosbuvir: The Failure of Pricing Policies In The European Union

2015 Value in Health

Lee, D. | Hanna, E. | El Hammi, E. | Rémuzat, C. | Toumi, M. | Volume: 18, Issue: 7, Pages: A572-A573,

Sofosbuvir, a breakthrough anti-HCV (hepatitis C virus) polymerase inhibitor, was first approved for early entry in 2012 in France. The product was granted a marketing authorisation in the United-States (US) and in the European Union (EU), by the end of 2013 and beginning of 2014, respectively. Shortly after licensing, most HTA bodies assessed sofosbuvir; they acknowledged a major additional benefit and find it cost-effective for a price around USD 80,000 in US and USD 55,000 in EU for a 12-week course treatment

https://www.doi.org/10.1016/j.jval.2015.09.1893